Private Equity PE Fund Investments
CDMO OneSource Pharma raises funding from 360 ONE Asset
Source OneSource Specialty Pharma (opens in a new tab)Yourstory (opens in a new tab)
360 ONE Asset has acquired a stake in Bengaluru-based OneSource Specialty Pharma , a contract development and manufacturing organisation (CDMO) specialising in biologics, complex injectables, and drug-device combinations. The deal involves buying out an existing investor’s stake.OneSource manufactures products such as GLP-1 drugs, which use a compound similar to those present in the popular obesity and diabetes drug, Ozempic. It also produces novel biologics or medicines derived from living organisms.
Between Feb 2016 and Oct 2024, OneSource had raised about USD 300 M from HBM Healthcare Investments, Motilal Oswal Alternates, Volrado Ventures, White Oak Capital Management, GMS Holdings, Think Investments and TPG Growth.